Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

ISS - THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2025

Company: Theranexus Date: 2025-01-23 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.pdf) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

![](_page_0_Picture_0.jpeg)

## **THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2025**

**Lyon, France – January 23, 2025, 6:00 PM CET -** Theranexus, an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces its financial communication agenda for 2025. Each publication will be released after Euronext market closing, unless otherwise specified. These dates are given as an indication, they are likely to be modified if necessary.

## **Indicative calendar**

| Events                                                     | Dates                     |
|------------------------------------------------------------|---------------------------|
| Cash position as at<br>December 31, 2024                   | 13<br>February<br>2025    |
| 2024<br>Annual<br>Results and Cash position as at 31/03/25 | 29<br>April<br>2025       |
| Shareholders' General Meeting                              | 26<br>June<br>2025, 10 am |
| Cash position as at June 30, 2025                          | 10 July 2025              |
| 2025 Half-Year Results<br>as at June 30 2025               | 25 September 2025         |
| Cash position as at September 30, 2025                     | 23 October 2025           |

## **About Theranexus**

Theranexus is an innovative biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company has a unique platform for the identification and characterization of advanced therapy drug candidates targeting rare neurological disorders and an initial drug candidate in clinical development for Batten disease.

Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).

For more information : [http://www.theranexus.com](http://www.theranexus.com/) Follow us on Twitter et LinkedIn

![](_page_0_Picture_9.jpeg)

**Contacts:** 

**THERANEXUS Christine PLACET** Chief Financial Officer [contact@theranexus.com](mailto:contact@theranexus.com)

**FP2COM Florence PORTEJOIE** Medias relations + 33 (0)6 07 76 82 83 [fportejoie@fp2com.fr](mailto:fportejoie@fp2com.fr)

## **Disclaimer**

This press release and the information contained herein do not constitute an offer of sale, purchase or subscription or the solicitation of a sale, purchase or subscription order for Theranexus shares in any country.

This press release contains certain forward-looking statements concerning Theranexus and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Theranexus considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document filed by the Company with the French regulator, Autorité des marchés financiers (AMF) on 30 April 2024 under number D.24-0382, which is available on the Company website [\(www.theranexus.com\)](http://www.theranexus.com/).

The reader's attention is particularly drawn to the fact that the Company's current financing horizon is limited to Q1 2026 (taking the aforementioned payments into account) and that, given its financing requirements and dilutive instruments in circulation, the Company's shareholders are likely to experience significant dilution of their stake in the Company in the short or medium term. The Company is also subject to other risks and uncertainties, including the development of economic conditions, the financial markets and the markets in which Theranexus operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Theranexus or not currently considered material by Theranexus.

The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Theranexus to be materially different from such forward-looking statements. Theranexus expressly declines any obligation to update such forward-looking statements.

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.